Repros Therapeutics (RPRX) Granted FDA Type B meeting on Proellex

February 28, 2013 9:27 AM EST Send to a Friend
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex® as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application.

Once the meeting is held, the Company will report the outcome to the financial community in a timely fashion.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA

Add Your Comment